Picard Medical, Inc. (NYSE:PMI) shares jumped 15% to $0.31 after the bell on Tuesday after the Tucson-based medtech announced successful acute in vivo implant studies of its next-generation Emperor Total Artificial Heart (Emperor TAH) platform, conducted at the University of Arizona and Banner University Medical Center.



<h2>Next-Gen Artificial Heart Clears Animal Study</h2>



According to the company, three procedures confirmed stable hemodynamic support with no device-related intraoperative failures. The electromechanical system features an independent dual-motor ventricular design enabling side-specific control of systemic and pulmonary circulation, building on the established architecture and clinical experience of the company’s FDA- and Health Canada-approved SynCardia Total Artificial Heart.



CEO Patrick Schnegelsberg called it “another important milestone” toward a fully implantable heart. 



The Emperor TAH has not yet received FDA approval.



<h2>Leadership Shakeup</h2>



On Monday, a Securities and Exchange Commission filing disclosed the termination of CFO Bernard Skaggs, with Georgina Smith appointed Chief Accounting Officer.



<h2>Trading Metrics, Technical Analysis</h2>



Picard Medical has a market capitalization of $24.70 million, with a 52-week high of $13.68 and a 52-week low of $0.11.



The stock of the biotechnology company has a Relative Strength Index (RSI) of 44.09.



Over the past 12 months, PMI has dropped 94.12%.



The small-cap stock is currently trading close its annual low.



PMI's sharp decline and weak positioning suggest continued pressure on shares, highlighting elevated risk and the need for clear signs of a turnaround before investor sentiment improves.



Price Action: According to Benzinga Pro data, the stock closed the regular session at $0.27, down 60.67%.



Benzinga's Edge Stock Rankings indicate that PMI has a negative price trend across all time frames.



<figure class="wp-block-image aligncenter size-full is-resized"></figure>



Photo Courtesy: Proxima Studio on Shutterstock.com



Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.



<div>



Read Also:

BlackBerry Stock Trends, Hovers Near 52-Week High After Hours: What's Going On?



</div>

Picard Medical (PMI) shares surged 15% after hours following successful in vivo studies of its Emperor Total Artificial Heart platform. The company reported stable hemodynamic support with no device-related failures in animal trials. Concurrently, the firm announced a leadership change, terminating CFO Bernard Skaggs and appointing Georgina Smith as Chief Accounting Officer.

Artificial Heart Maker Picard Medical's Stock Surges 15% After Hours: Here's What's Going On With PMI